Vertex Pharmaceuticals has announced the discontinuation of its Phase 1/2 study of VX-522, an inhaled mRNA therapy for cystic fibrosis developed in collaboration with Moderna. Persistent lung inflammation issues in trial participants led to this decision, highlighting ongoing challenges in delivering nucleic acids to the lungs without triggering immune responses. The discontinuation robs approximately 5,000 cystic fibrosis patients who do not benefit from existing treatments of a potential new option. Both companies plan to apply lessons learned from this setback to future developments while Vertex will shift focus to alternative treatments. The news serves as a reminder of the complexities involved in pulmonary drug delivery.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://hoodline.com/2026/05/vertex-axes-moderna-cystic-fibrosis-trial-rattling-boston-biotech/
